Cabot Co. (NYSE:CBT) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC lowered its stake in shares of Cabot Co. (NYSE:CBT - Free Report) by 73.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,734 shares of the specialty chemicals company's stock after selling 7,752 shares during the quarter. Guggenheim Capital LLC's holdings in Cabot were worth $250,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of CBT. Norges Bank acquired a new position in shares of Cabot in the 4th quarter valued at about $37,961,000. Copeland Capital Management LLC boosted its holdings in Cabot by 21.6% in the 4th quarter. Copeland Capital Management LLC now owns 761,372 shares of the specialty chemicals company's stock worth $69,521,000 after buying an additional 135,119 shares during the last quarter. American Century Companies Inc. increased its stake in Cabot by 8.5% during the 4th quarter. American Century Companies Inc. now owns 1,323,347 shares of the specialty chemicals company's stock worth $120,835,000 after buying an additional 103,380 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Cabot by 27.1% in the fourth quarter. JPMorgan Chase & Co. now owns 451,513 shares of the specialty chemicals company's stock worth $41,228,000 after acquiring an additional 96,179 shares during the last quarter. Finally, Lightrock Netherlands B.V. acquired a new position in Cabot in the 4th quarter valued at $6,228,000. 93.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CBT has been the subject of a number of analyst reports. Mizuho dropped their price target on Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. decreased their price objective on Cabot from $105.00 to $85.00 and set an "underweight" rating on the stock in a report on Friday, February 21st. StockNews.com raised Cabot from a "hold" rating to a "buy" rating in a research report on Thursday, April 17th. Finally, UBS Group lowered their price objective on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a research note on Monday, April 7th.

Cabot Stock Down 0.2 %

Cabot stock traded down $0.17 during midday trading on Wednesday, reaching $78.55. The company's stock had a trading volume of 587,896 shares, compared to its average volume of 393,337. The business has a 50-day simple moving average of $81.48 and a 200-day simple moving average of $93.14. The company has a market cap of $4.26 billion, a P/E ratio of 10.43, a P/E/G ratio of 0.74 and a beta of 1.04. Cabot Co. has a fifty-two week low of $73.63 and a fifty-two week high of $117.46. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72.

Cabot (NYSE:CBT - Get Free Report) last posted its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. On average, research analysts expect that Cabot Co. will post 7.57 earnings per share for the current fiscal year.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.